Matches in SemOpenAlex for { <https://semopenalex.org/work/W2166839079> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W2166839079 endingPage "A418" @default.
- W2166839079 startingPage "A418" @default.
- W2166839079 abstract "To examine the incremental costs of chemotherapy-associated AEs in mBC The PharMetrics Database (2000-2010) was used to identify mBC patients treated with first- or second-line taxane (paclitaxel or docetaxel) or capecitabine-based regimens, with treatment episodes (TEs) ≥30 days. Inverse probability weighting was used to balance patient characteristics between cohorts with and without AEs. Incremental costs attributable to AEs were assessed by comparing costs incurred during TEs with and without AEs and included the following components: inpatient, outpatient, emergency room, other medical service, pharmacy costs, and total health care costs. Sensitivity analyses were conducted to examine the average monthly costs in patients cohorts stratified by the number and type of AEs reported during the TEs. 3,222 women (mean age=57) received a first- and/or second-line taxane or capecitabine for mBC. Of the 2,678 1st-line patients, 69.7% received taxane and 30.3% capecitabine. AEs were commonly seen in patients treated with first-line taxane (94.6%) and capecitabine (83.7%). On average, the total monthly incremental cost associated with AEs was 38% higher ($3,547) for taxane and 9% higher ($854) for capecitabine. Inpatient and other drug costs accounted for a majority of the increased costs. Of 1,084 second-line patients, 66.0% received taxane and 34.0% with capecitabine. 94.4% of second-line taxane patients and 84% of capecitabine patients had an AE. The average total monthly incremental cost associated with AEs for taxane was $5,320 and $4,933 for capecitabine (69.5% and 82.9% higher vs. patients without AEs). Differences in pharmacy costs drove the incremental AE-related costs in taxanes users; inpatient and outpatient costs accounted for the majority of these costs in capecitabine users. Sensitivity analyses showed a clear trend of an increasing economic burden with the number of AEs. Chemotherapy-related AEs are associated with a substantial economic burden primarily explained by increased inpatient, outpatient, and pharmacy costs." @default.
- W2166839079 created "2016-06-24" @default.
- W2166839079 creator A5032187510 @default.
- W2166839079 creator A5033092533 @default.
- W2166839079 creator A5035592082 @default.
- W2166839079 creator A5041026389 @default.
- W2166839079 creator A5045788834 @default.
- W2166839079 creator A5068059897 @default.
- W2166839079 creator A5072015843 @default.
- W2166839079 creator A5089194015 @default.
- W2166839079 date "2012-11-01" @default.
- W2166839079 modified "2023-09-26" @default.
- W2166839079 title "PCN51 Comprehensive Investigation of Adverse Event (AE)-Related Costs in Patients With Metastatic Breast Cancer (mBC) Treated With First- and Second-Line Chemotherapies" @default.
- W2166839079 doi "https://doi.org/10.1016/j.jval.2012.08.1244" @default.
- W2166839079 hasPublicationYear "2012" @default.
- W2166839079 type Work @default.
- W2166839079 sameAs 2166839079 @default.
- W2166839079 citedByCount "0" @default.
- W2166839079 crossrefType "journal-article" @default.
- W2166839079 hasAuthorship W2166839079A5032187510 @default.
- W2166839079 hasAuthorship W2166839079A5033092533 @default.
- W2166839079 hasAuthorship W2166839079A5035592082 @default.
- W2166839079 hasAuthorship W2166839079A5041026389 @default.
- W2166839079 hasAuthorship W2166839079A5045788834 @default.
- W2166839079 hasAuthorship W2166839079A5068059897 @default.
- W2166839079 hasAuthorship W2166839079A5072015843 @default.
- W2166839079 hasAuthorship W2166839079A5089194015 @default.
- W2166839079 hasBestOaLocation W21668390791 @default.
- W2166839079 hasConcept C104863432 @default.
- W2166839079 hasConcept C121608353 @default.
- W2166839079 hasConcept C126322002 @default.
- W2166839079 hasConcept C143998085 @default.
- W2166839079 hasConcept C2775930923 @default.
- W2166839079 hasConcept C2776421732 @default.
- W2166839079 hasConcept C2777511904 @default.
- W2166839079 hasConcept C2777909004 @default.
- W2166839079 hasConcept C2780192828 @default.
- W2166839079 hasConcept C2781190966 @default.
- W2166839079 hasConcept C512399662 @default.
- W2166839079 hasConcept C526805850 @default.
- W2166839079 hasConcept C530470458 @default.
- W2166839079 hasConcept C61367390 @default.
- W2166839079 hasConcept C71924100 @default.
- W2166839079 hasConceptScore W2166839079C104863432 @default.
- W2166839079 hasConceptScore W2166839079C121608353 @default.
- W2166839079 hasConceptScore W2166839079C126322002 @default.
- W2166839079 hasConceptScore W2166839079C143998085 @default.
- W2166839079 hasConceptScore W2166839079C2775930923 @default.
- W2166839079 hasConceptScore W2166839079C2776421732 @default.
- W2166839079 hasConceptScore W2166839079C2777511904 @default.
- W2166839079 hasConceptScore W2166839079C2777909004 @default.
- W2166839079 hasConceptScore W2166839079C2780192828 @default.
- W2166839079 hasConceptScore W2166839079C2781190966 @default.
- W2166839079 hasConceptScore W2166839079C512399662 @default.
- W2166839079 hasConceptScore W2166839079C526805850 @default.
- W2166839079 hasConceptScore W2166839079C530470458 @default.
- W2166839079 hasConceptScore W2166839079C61367390 @default.
- W2166839079 hasConceptScore W2166839079C71924100 @default.
- W2166839079 hasIssue "7" @default.
- W2166839079 hasLocation W21668390791 @default.
- W2166839079 hasOpenAccess W2166839079 @default.
- W2166839079 hasPrimaryLocation W21668390791 @default.
- W2166839079 hasRelatedWork W181195935 @default.
- W2166839079 hasRelatedWork W1966024431 @default.
- W2166839079 hasRelatedWork W1978529448 @default.
- W2166839079 hasRelatedWork W2004396656 @default.
- W2166839079 hasRelatedWork W2085123446 @default.
- W2166839079 hasRelatedWork W2135287852 @default.
- W2166839079 hasRelatedWork W2406160662 @default.
- W2166839079 hasRelatedWork W2415167417 @default.
- W2166839079 hasRelatedWork W4232088779 @default.
- W2166839079 hasRelatedWork W4253360580 @default.
- W2166839079 hasVolume "15" @default.
- W2166839079 isParatext "false" @default.
- W2166839079 isRetracted "false" @default.
- W2166839079 magId "2166839079" @default.
- W2166839079 workType "article" @default.